La Jolla Pharmaceutical Conference Call to Discuss Positive 12-Month Interim Antibody Data and Provide Update for Ongoing Riquent(R) Phase 3 'ASPEN' Lupus Trial  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Apr 23 Calls Today's Calls

Call Details La Jolla Pharmaceutical Conference Call to Discuss Positive 12-Month Interim Antibody Data and Provide Update for Ongoing Riquent(R) Phase 3 'ASPEN' Lupus Trial Wed, Apr 23, 2008, 4:30 pm Eastern Listen to the archived event audio About La Jolla Pharmaceutical Company (NasdaqGM:LJPC) La Jolla Pharmaceutical Company, a biopharmaceutical company, develops pharmaceutical products to treat patients with lupus. The company's lead product in development is Riquent, which is in Phase 3 ASPEN clinical trials to treat patients with lupus. The Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. It also discovers and develops orally-active small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. The company was founded in 1989 and is based in San Diego, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings